Redhill Biopharma Ltd. (NASDAQ:RDHL) – Analysts at Seaport Global Securities decreased their FY2017 earnings estimates for shares of Redhill Biopharma in a report issued on Monday, Zacks Investment Research reports. Seaport Global Securities analyst V. Bernardino now expects that the biotechnology company will post earnings per share of ($2.52) for the year, down from their previous estimate of ($2.46). Seaport Global Securities currently has a “Buy” rating and a $19.00 target price on the stock. Seaport Global Securities also issued estimates for Redhill Biopharma’s Q4 2017 earnings at ($0.50) EPS.
A number of other brokerages have also recently issued reports on RDHL. Roth Capital reissued a “buy” rating and set a $27.00 price objective on shares of Redhill Biopharma in a report on Wednesday, October 4th. Zacks Investment Research raised Redhill Biopharma from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of Redhill Biopharma in a report on Tuesday, November 21st. Finally, UBS started coverage on Redhill Biopharma in a report on Wednesday, September 13th. They set a “reduce” rating for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. Redhill Biopharma presently has an average rating of “Buy” and an average target price of $21.10.
Shares of Redhill Biopharma (RDHL) traded up $0.35 during midday trading on Wednesday, hitting $4.95. The company’s stock had a trading volume of 240,159 shares, compared to its average volume of 97,728. Redhill Biopharma has a 12 month low of $4.30 and a 12 month high of $11.99.
Several institutional investors have recently added to or reduced their stakes in RDHL. Bank of New York Mellon Corp bought a new position in shares of Redhill Biopharma in the first quarter valued at about $101,000. Renaissance Technologies LLC raised its holdings in shares of Redhill Biopharma by 144.1% in the first quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 36,600 shares during the last quarter. Oppenheimer & Co. Inc. raised its holdings in shares of Redhill Biopharma by 10.8% in the second quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock valued at $220,000 after buying an additional 2,500 shares during the last quarter. D.A. Davidson & CO. raised its holdings in shares of Redhill Biopharma by 10.0% in the second quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 4,000 shares during the last quarter. Finally, Family Management Corp raised its holdings in shares of Redhill Biopharma by 51.5% in the second quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock valued at $222,000 after buying an additional 8,750 shares during the last quarter. 8.47% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This news story was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2017/12/07/fy2017-eps-estimates-for-redhill-biopharma-ltd-rdhl-lowered-by-seaport-global-securities-updated-updated.html.
Redhill Biopharma Company Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.